The long-term objective of this study is to identify biochemical pathways that can be used to diagnose and treat human cancers. This study will focus on central carbon metabolism, a process including the uptake and usage of glucose for energy production, cellular biosynthesis, and cell reproduction. Specifically, the work will center on cells in which the tumor suppresser PTEN is inactivated. Since PTEN is frequently inactivated in cancers, including those of the breast, prostate, ovary, endometrium and skin, the work will be relevant to a wide range of human cancers. The study seeks to test the hypothesis that inactivation of PTEN is associated with significant changes in central metabolism, and that some of these metabolic pathways may be exploited as therapeutic and prognostic targets in human cancers. Our preliminary results point to PTEN-dependent changes in metabolic flux in melanoma cells. To test this hypothesis the Specific Aims are to address the following questions using melanoma cell systems as a model: 1) What are the differences in central carbon metabolism in PTEN* and PTEN inactive tumors? 2) What metabolic pathways can be exploited as drug targets in PTEN inactive melanomas? 3) What are the effects of drugs on central metabolism in PTEN* and PTEN inactive melanoma cells? 4) Can we identify subsets of PTEN inactive tumors that are highly responsive to a metabolic blockade? The prinriary approach for the study is an analysis of carbon flux through central metabolism using 2D HSQC NMR. Flux through glycolysis, the pentose phosphate pathway, the TCA cycle, and fatty acid biosynthesis, will be quantified and compared under a number of conditions that are known to alter the function of the PTEN pathway. The studies will also define the concentrations of more then twenty key metabolites. Altogether the information gained form this work should provide an understanding how the mechanistic connections occur between PTEN/PI3K/Akt and central metabolism. It is anticipated that the work will also reveal new diagnostic and therapeutic targets.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sanford-Burnham Medical Research Institute
La Jolla
United States
Zip Code
Poothong, Juthakorn; Sopha, Pattarawut; Kaufman, Randal J et al. (2017) IRE1? nucleotide sequence cleavage specificity in the unfolded protein response. FEBS Lett 591:406-414
Falletta, Paola; Sanchez-Del-Campo, Luis; Chauhan, Jagat et al. (2017) Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev 31:18-33
Jin, Jung-Kang; Blackwood, Erik A; Azizi, Khalid et al. (2017) ATF6 Decreases Myocardial Ischemia/Reperfusion Damage and Links ER Stress and Oxidative Stress Signaling Pathways in the Heart. Circ Res 120:862-875
Grootjans, Joep; Kaser, Arthur; Kaufman, Randal J et al. (2016) The unfolded protein response in immunity and inflammation. Nat Rev Immunol 16:469-84
Han, Jaeseok; Kaufman, Randal J (2016) The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res 57:1329-38
Bai, Yongsheng; Kinne, Jeff; Donham, Brandon et al. (2016) Read-Split-Run: an improved bioinformatics pipeline for identification of genome-wide non-canonical spliced regions using RNA-Seq data. BMC Genomics 17 Suppl 7:503
Placzek, Andon N; Prisco, Gonzalo Viana Di; Khatiwada, Sanjeev et al. (2016) eIF2?-mediated translational control regulates the persistence of cocaine-induced LTP in midbrain dopamine neurons. Elife 5:
Wang, Miao; Kaufman, Randal J (2016) Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 529:326-35
Jeon, Young Joo; Khelifa, Sihem; Ratnikov, Boris et al. (2015) Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell 27:354-69
Qi, Jianfei; Ronai, Ze'ev A (2015) Dysregulation of ubiquitin ligases in cancer. Drug Resist Updat 23:1-11

Showing the most recent 10 out of 42 publications